Status:
COMPLETED
A Study of RO4989991 in Patients With Allergic Rhinitis
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Asthma
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This multi-center, randomized, observer-blinded, placebo-controlled study will evaluate the safety and tolerability of subcutaneous doses of RO4989991 in patients with allergic rhinitis who are otherw...
Eligibility Criteria
Inclusion
- Adult patients, 18-65 years of age, inclusively
- A history of allergic rhinitis diagnosed by a physician, but otherwise healthy
- A positive skin prick test to at least one standardized allergen at screening
- A body mass index (BMI) between 18 and 32 kg/m2, inclusively
Exclusion
- History or presence of any respiratory disease or condition other than allergic rhinitis
- Use of prescription medication or herbal remedies within 14 days of dosing the study drug
- Use of over-the-counter (OTC) medications within 7 days of dosing the study drug
- Acute infection (including viral infections) 6 weeks (8 weeks for respiratory infections) preceding dosing or any ongoing chronic infection
- Positive test for human immunodeficiency virus (HIV) or hepatitis B or C
Key Trial Info
Start Date :
July 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2011
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT01152619
Start Date
July 1 2010
End Date
February 1 2011
Last Update
November 2 2016
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
South Miami, Florida, United States, 33143
2
Normal, Illinois, United States, 61761
3
Raleigh, North Carolina, United States, 27612
4
Spartanburg, South Carolina, United States, 29303